Pfizer's revenue has stabilized, and a recent drug pricing deal with the US government reduces political uncertainty. Find ...

Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show ...

Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

Astellas Pharma and Pfizer recently announced positive Phase 3 results for PADCEV plus KEYTRUDA in muscle-invasive bladder ...

QSM Asset Management added 276,899 shares of Pfizer for an estimated $6.8 million in the third quarter. After the transaction ...

According to a Securities and Exchange Commission (SEC) filing dated October 16, 2025, ASSET PLANNING SERVICES INC /LA/ /ADV ...

Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New ...

Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...

Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...